Dexmedetomidine Preconditioning Protects Rats from Renal Ischemia-Reperfusion Injury Accompanied with Biphasic Changes of Nuclear Factor-Kappa B Signaling

J Immunol Res. 2020 Apr 17:2020:3230490. doi: 10.1155/2020/3230490. eCollection 2020.

Abstract

Acute kidney injury (AKI) is one of the most common and troublesome perioperative complications. Dexmedetomidine (DEX) is a potent α2-adrenoceptor (α2-AR) agonist with anti-inflammatory and renoprotective effects. In this study, a rat renal ischemia-reperfusion injury (IRI) model was induced. At 24 h after reperfusion, the IRI-induced damage and the renoprotection of DEX preconditioning were confirmed both biochemically and histologically. Changes in nuclear factor-kappa B (NF-κB), as well as its downstream anti-inflammatory factor A20 and proinflammatory factor tumor necrosis factor-α (TNF-α), were detected. Atipamezole, a nonselective antagonist, was then added 5 min before the administration of DEX to further analyze DEX's effects on NF-κB, and another anti-inflammatory medicine, methylprednisolone, was used in comparison with DEX, to further analyze DEX's effects on NF-κB. Different concentrations of DEX (0 nM, 0.1 nM, 1 nM, 10 nM, 100 nM, 1 μM, and 10 μM) were applied to preincubated human renal tubular epithelial cell line (HK-2) cells in vitro. After anoxia and reoxygenation, the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) tetrazolium assay and enzyme-linked immunosorbent assay (ELISA) were performed to evaluate the levels of NF-κB downstream anti-inflammatory cytokines. The results showed that, unlike methylprednisolone, DEX preconditioning led to a time-dependent biphasic change (first activation then inhibition) of NF-κB in the rat renal IRI models that were given 25 μg/kg i.p. It was accompanied by a similarly biphasic change of TNF-α and an early and persistent upregulation of A20. In vitro, DEX's cellular protection showed a concentration-dependent biphasic change which was protective within the range of 0 to 100 nM but became opposite when concentrations are greater than 1 μM. The changes in the A20 and NF-κB messenger RNA (mRNA) levels were consistent with the renoprotective ability of DEX. In other words, DEX preconditioning protected the rats from renal IRI via regulation biphasic change of NF-κB signaling.

MeSH terms

  • Acute Kidney Injury / etiology
  • Acute Kidney Injury / prevention & control*
  • Adrenergic alpha-2 Receptor Agonists / therapeutic use*
  • Animals
  • Anti-Inflammatory Agents / therapeutic use*
  • Cell Line
  • Dexmedetomidine / therapeutic use*
  • Disease Models, Animal
  • Humans
  • Ischemic Preconditioning / methods*
  • Kidney / metabolism*
  • Kidney / pathology
  • Male
  • NF-kappa B / metabolism
  • Rats
  • Rats, Sprague-Dawley
  • Reperfusion Injury / etiology
  • Reperfusion Injury / prevention & control*
  • Signal Transduction
  • Tumor Necrosis Factor alpha-Induced Protein 3 / metabolism
  • Tumor Necrosis Factor-alpha / metabolism

Substances

  • Adrenergic alpha-2 Receptor Agonists
  • Anti-Inflammatory Agents
  • NF-kappa B
  • Tumor Necrosis Factor-alpha
  • Dexmedetomidine
  • TNFAIP3 protein, rat
  • Tumor Necrosis Factor alpha-Induced Protein 3